ArticleThe New England journal of medicine2017
Nivolumab and Ipilimumab in Advanced Melanoma.
Article in The New England journal of medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed.
- Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2021Trial
- Trial
- Association of sodium-glucose co-transport protein 2 inhibitor use with clinical outcomes in patients receiving immune checkpoint inhibitors: a pan-tumor propensity-matched analysis.The oncologist · 2026Article
- The Landmark Series: Melanoma and Adjuvant Therapy.Annals of surgical oncology · 2025Review
- Intratumoral administration of mRNA COVID-19 vaccine delays melanoma growth in mice.Scientific reports · 2025Article
- Lag3 and PD-1 pathways preferentially regulate NFAT-dependent TCR signalling programmes during early CD4Immunotherapy advances · 2025Article
- Targeting Upregulated cIAP2 in SOX10-Deficient Drug Tolerant Melanoma.Molecular cancer therapeutics · 2023Article
- Metabolic rewiring induced by ranolazine improves melanoma responses to targeted therapy and immunotherapy.Nature metabolism · 2023Article
- Targeting PD-1/PD-L1 in cancer immunotherapy: An effective strategy for treatment of triple-negative breast cancer (TNBC) patients.Genes & diseases · 2023Review
- Article
- Soluble CTLA-4 mutants ameliorate immune-related adverse events but preserve efficacy of CTLA-4- and PD-1-targeted immunotherapy.Science translational medicine · 2023Article
- SARS-CoV-2 infection in patients with melanoma: results of the Spanish Melanoma Group registry.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2023Article
- Establishment and immune phenotyping of patient-derived glioblastoma models in humanized mice.Frontiers in immunology · 2023Article
- A Review of Immune Checkpoint Blockade for the General Surgeon.The Journal of surgical research · 2023Review
- Spinal Metastases and the Evolving Role of Molecular Targeted Therapy, Chemotherapy, and Immunotherapy.Neurospine · 2022Article
- Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockade.Journal for immunotherapy of cancer · 2022Article
- COVID-19 vaccine development from the perspective of cancer patients.Human vaccines & immunotherapeutics · 2021Review
- Predicting development of ipilimumab-induced hypophysitis: utility of T4 and TSH index but not TSH.Journal of endocrinological investigation · 2021Article
- Biologic subtypes of melanoma predict survival benefit of combination anti-PD1+anti-CTLA4 immune checkpoint inhibitors versus anti-PD1 monotherapy.Journal for immunotherapy of cancer · 2021Article
- Outcomes after resumption of immune checkpoint inhibitor therapy after high-grade immune-mediated hepatitis.Cancer · 2020Article
Corrections and comments
- Comment on
- Comment on
- Erratum issued
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
29262279What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.